|
|
|
| |
CRU Organization
Dean, Faculty of Tropical Medicine
Chief, Clinical Trial Project
Staffs
 |
|
| |
|
|
|
|
|
| |
| | |
|
| |
| |
About VTC
>
![]()
| |
| |
|
| |
|
Enrollment and
retention rate of various projects conducted by
VTC
|
|
|
Protocols |
Date of
activation |
Total
Enrolled |
% Expected
Enrolled |
Total visit
Retention (%) |
Total visits
Expected |
|
gp120/alum, subtype B (phase
I/II)
|
February 1995 - December
1996 |
33 |
100% |
693 (100) |
693 |
|
gp120/MF59, subtype E
antigen alone or combined with B antigen (phase
I/II)
|
1997-1999 |
370 |
100% |
783 (99.87) |
784 |
|
gp120/alum, combined subtype
B (AIDSVAX® B/E)
(phase I/II)
|
January 1998 - August
1999 |
92 |
100% |
1,158 (96.82) |
1,196 |
|
gp120/alum, combined subtype
B,E (AIDSVAX® B/E)
(phase I/II)
|
March 1999 - 2003 |
2,500 |
100% |
35,041 (91.79) |
38,175 |
|
ALVAC-HIV rgp 120 B/E boost
(phase I/II)
|
2000-2002 |
123
(VTC 62) |
100% |
587 (97.83) |
600 |
|
ALVAC-HIV rgp 120 B/E boost
(phase III)
|
September 2003 -
present |
6,963 |
On process
Recruitment |
83.354 (89.19)* |
93.456* |
|
MRKAd5 HIV-1 gag vaccine
(phase I)
|
November 2003 - present |
87
(VTC 29) |
100% |
471 (98.33)** |
479** |
|
Overall Protocols
|
7 |
|
|
| |
|
* recruitment is on process,
data available as of May 31, 2005
** study
is on going, data available as of May, 2005
<<
Back | | | | | |
|
